The influence of Simvastatin and Korargin on the clinical course of coronary heart disease, body weight and distribution of adipose tissue in patients with type 2 diabetes mellitus.
DOI:
https://doi.org/10.14739/2310-1210.2013.3.13574Abstract
Diabetes mellitus (DM) is one of the most influential risk factors for the development of cardiovascular diseases. Incidence of coronary heart diseases (CHD) and acute myocardial infarction in diabetic patients is much higher than in people without diabetes. Type 2 DM affects other risk factors of CHD due to the fact that, as a rule, it is accompanied by obesity, hypertension, hypertriglyceridemia and decrease of high density lipoproteins.
Purpose of the investigation – to improve the efficiency of treatment of patients with CHD with type 2 DM based on the effect of Simvastatin and Korargin on it’s clinical course, body weight and the distribution of adipose tissue.
Materials and methods of the investigation. The study involved 175 patients with CHD aged from 34 to 87, mean age was 61,0 ± 8,0 years, among whom there were 96 (54,9%) men and 79 (45,1%) women. All surveyed received conventional treatment. Depending on supplementary prescriptions patients were divided into eight groups: 1 group - 22 patients with CHD who were prescribed Simvastatin, 2 group - 20 patients with CHD who were prescribed Korargin, 3 group - 20 patients with coronary artery disease who were prescribed simultaneously both Simvastatin and Korarhin, 4 group - 20 patients with CHD with type 2 diabetes treated with Simvastatin, 5 group - 23 patients with CHD with type 2 diabetes who took Korargin, 6 group - 27 patients with CHD with type 2 diabetes, who were prescribed both Simvastatin and Korargin in addition to conventional treatments, 7 group - 20 patients with CHD who received only conventional treatments, 8 group - 23 patients with coronary artery disease combined with type 2 diabetes who received only conventional treatments. Simvastatin ("Vazostat-Health" FC "Health", Kharkiv) was administered at a daily dose of 20 mg at night during 6 months, Korargin (JSC "Engineer", Uman) - 0,1 g of L-arginine hydrochloride with 0.1 g of inosine – was administered at a dose of 3 tablets twice per daily before meals for 2 months.
Findings of the investigation and discussion. The most prominent clinical effect on major clinical indicators of CHD (the average number of angina attacks per day, the average duration of angina attacks and nitroglycerin daily dose) in CHD patients with type 2 DM was provided with the combination of Simvastatin and Korargin on the background of the conventional treatments, due to the combined action of two drugs with different mechanisms of actions synergistically improving endothelial function.
The body weight and distribution of adipose tissue in patients with CHD with type 2 DM (waist size, hip size, and WS/HS) were significantly more pronounced on the background of treatment with Simvastatin combined with Korargin.
Conclusion:
- The supplement of Simvastatin and Korragin to the conventional treatment of patients with CHD with type 2 DM increases effort tolerance.
- Changes of body weight and distribution of adipose tissue in these patients are significantly more prominent on the background of Simvastatin and Korargin intake.
Key words: coronary heart disease, diabetes, simvastatin, korargin.
Downloads
Published
How to Cite
Issue
Section
License
Authors who publish with this journal agree to the following terms:- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access)
